News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

H. Lundbeck A/S (LUN.CO)'s Brintellix® (Vortioxetine) For The Treatment Of Major Depressive Disorder In Adults Is Now Available In U.S. Pharmacies


1/21/2014 9:12:56 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Valby, Denmark and Osaka, Japan, 2014-01-21 15:00 CET (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceuticals Company Limited (Takeda) jointly announced today that Brintellix (vortioxetine), for the treatment of major depressive disorder (MDD) in adults, is available in pharmacies across the United States (U.S.) – following initial availability through wholesalers soon after its September 30 approval by the U.S. Food and Drug Administration. Brintellix is a once-daily oral antidepressant available in a range of doses, to help address the variability of patient needs.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES